Based on its potent preclinical efficacy, PF-06873600 progressed to a first-in-human Phase 1/2a clinical trial in patients with advanced solid tumors, including HR+/HER2-breast cancer, TNBC, and ovarian cancer. Here, HR is linked to breast carcinoma.